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Abstract The insulin receptor (IR) and the insulin-like growth
factor-I receptor (IGF-1R) show differential binding of insulin
and IGFs. The specificity determinants for IGF-1 binding are
known to be located in the cysteine-rich (Cys-rich) region
between residues 223 and 274 of human IGF-1R, which includes
a loop that protrudes into the putative ligand binding site. In this
report we have replaced residues 260^277 of human IR with
residues 253^266 of the human IGF-1R to produce an IR-based,
cysteine loop exchange chimaera, termed hIR-Cys loop exchange
(CLX), in which all 14 amino acid residues in the exchanged loop
differ from wild-type insulin receptor. This loop exchange had a
detrimental effect on the efficiency of pro-receptor processing
and on the binding of the mouse monoclonal antibody 83-7.
However, this antibody, which binds hIR but not hIGF-1R, was
still capable of immunoprecipitating the mature chimaeric
receptor, indicating that the conformational epitope recognised
by this antibody is not primarily determined by the loop region
exchanged. The loop exchange did not significantly affect the
ability of insulin to displace bound radiolabelled insulin, but
increased the capacity of IGF-1 to competitively displace labelled
insulin by at least 10 fold.
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1. Introduction
The ectodomains of members of the insulin receptor (IR)
family are dimers made up of several modular units. The N-
terminal half of the ectodomain contains two homologous
domains, L1 and L2, separated by a Cys-rich region
(Cys159^Cys308) [1^3]. The C-terminal half consists of three
¢bronectin type III domains, the second of which contains a
large insert domain that includes the protease cleavage site
that generates the K and L chains [4^7].
The role of di¡erent extracellular regions of these receptors
in ligand binding has been established through studies involv-
ing either chemical cross-linking, receptor fragments or chi-
maeric receptors. Chemical cross-linking with derivatised
ligands labels only the K-chains of the receptor [8^10].
Furthermore, expressed K-chains [11], or K-chain mini recep-
tors consisting of the L1/Cys-rich/L2 domains fused to the last
16 residues of the K-chain [12,13], bind ligand with compara-
ble a⁄nities to ectodomain dimers. The data obtained from
IR/IGF-1R chimaeras of both full length receptor and ecto-
domain established the importance of the Cys-rich region in
controlling IGF-1 binding speci¢city, but not insulin binding.
These studies mapped the determinants of IGF-1 speci¢city to
residues 223^274 in the Cys-rich region of IGF-1R [14^18].
These residues correspond to modules 4, 5 and 6 in the Cys-
rich region of IGF-1R with modules 5 and 6 located on one
side of the central cavity and possibly forming part of the
ligand binding site [3]. Module 6 has a mobile loop (residues
255^265) which extends into the central cavity of the L1/Cys-
rich/L2 fragment and is the most divergent Cys-rich module in
terms of sequence identity compared to IR, with 25 of the 31
residues being di¡erent. The corresponding region in IR is
larger, containing four additional residues and a disulphide
bond not present in IGF-1R [2] and has a markedly di¡erent
net charge with ¢ve basic residues and one acidic residue
compared to six acidic residues and one basic residue in mod-
ule 6 of hIGF-1R [3]. Thus the larger size and positive charge
of the loop in hIR may serve to perturb binding of IGF-1, so
reducing the a⁄nity of the receptor for this ligand, while
maintaining tight binding of the smaller insulin molecule.
To test this hypothesis, a mutant hIR was constructed in
which residues 260^277 of hIR were replaced by residues
253^266 of IGF-1R (Fig. 1) and the e¡ects on ligand binding
to this chimaeric receptor, termed hIR-Cys loop exchange
(CLX), were examined. In addition, the epitope for Mab
83-7 [19] which is known to be located within residues 191^
297 of the Cys-rich region of IR [11,20], has been further
mapped using this chimaera. Four of the seven sequence dif-
ferences between the mouse and human IR sequences within
the region 191^297 [21^23] are located within the variable
loop of module 6 that has been exchanged in this hIR-CLX
chimaera, making it a useful construct to further de¢ne the
83-7 epitope.
2. Materials and methods
2.1. Mutagenesis
The DNA used in these studies was derived from a full-length hIR
cDNA from plasmid peT [24]. A 1.0 kb EcoRI fragment of hIR
cDNA from plasmid peT, encoding the N-terminal sequence to amino
acid residue 296 [21], was introduced into M13mp18 [25] for muta-
genesis. Oligonucleotide-directed in vitro mutagenesis using the USB-
T7 Gen1 in vitro mutagenesis kit was employed to exchange nucle-
otide sequence encoding amino acid residues 260^277 inclusive of hIR
with the sequence encoding residues 253^266 inclusive of IGF-1R
(Fig. 1). Mutant clones were identi¢ed by colony hybridisation [26]
using an oligonucleotide probe 5P-end labelled with [Q-32P]ATP, and
were con¢rmed by sequence determination [27].
A vehicle for mammalian cell expression of hIR cDNA with which
the mutated fragment could be exchanged was prepared from expres-
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sion vector pEE14 (Celltech, Slough, UK [28] modi¢ed by deletion of
the EcoRI restriction site through ¢ll-in and religation. The hIR
cDNA for this construct was from plasmid peT, and was inserted
into the polylinker of the modi¢ed pEE14 expression vector as a
HindIII^XbaI fragment. The mutagenised DNA cloned in M13mp18
was exchanged with the corresponding part of hIR cDNA of this
expression vehicle by exchange of the 1.0 kb EcoRI fragments. These
procedures produced an expression vehicle encoding a mutant hIR
designated hIR-CLX, in which a segment of the sequence which forms
a loop within module 6 of the Cys-rich domain was replaced by the
shorter loop of the IGF-1R sequence with four fewer residues and
lacking the nested disulphide bond of the hIR sequence.
2.2. Cell culture, DNA transfection and protein analysis
For transient transfection assays, human 293T and African green
monkey-derived COS ¢broblasts maintained in DMEM plus 10%
foetal calf serum were transfected with plasmid DNA using FuGENE
(Roche Molecular Biochemicals) according to the manufacturers in-
structions. For ligand-binding studies, cells were seeded at 106 cells
per 10 cm plate prior to transfection. 24 h after transfection, cells were
harvested from 10 cm plates by trypsination and replated into poly-D-
lysine treated 96 well plates (Becton Dickinson) at 5U104 cells per
well (293T cells) or standard 24 well plates (COS cells). These cells
were cultured for a further 24 h prior to serum starvation for 4^5 h
and ligand binding studies (see below). For immunoprecipitation stud-
ies, 293T cell cultures were seeded at 3U105 cells per 3.5 cm plate. 48
h after transfection, cells were solubilised in NP-40 lysis bu¡er [29].
Solubilised receptors were immunoprecipitated from cell lysates with
the conformation-dependent, anti-K chain-speci¢c hIR monoclonal
antibodies 83-7 or 83-14 [19]. Immune complexes were collected on
protein A-Sepharose beads (Zymed Laboratories), fractionated by
SDS^polyacrylamide gel (7.5%) under reducing conditions and the
proteins transferred to nitrocellulose membranes [29]. Immunoblotting
of membranes was performed in 3% skim milk in TBST (10 mM Tris^
HCl, pH 7.5, 100 mM NaCl, 0.1% Tween 20) using the hIR L-chain-
speci¢c monoclonal antibody, CT-1 [30]. Bound antibody was de-
tected by probing with horseradish peroxidase-conjugated, rabbit
anti-mouse IgG (Santa Cruz Biotechnology) followed by detection
with Super Signal West Pico chemiluminescent substrate (Pierce).
2.3. Ligand binding assays
For binding analysis, adherent transiently transfected cells were
incubated in a total volume of 100 Wl (96 well plates; 293T cells) or
300 Wl (24 well plates; COS cells) with 40 pM [125I-Tyr A14]insulin
(Amersham) and varying concentrations of unlabelled ligand in bind-
ing bu¡er (100 mM HEPES, 120 mM NaCl, 15 mM Na acetate, 1.2
mM MgSO4, 10 mM glucose, 0.5% w/v BSA, pH 7.8) for 1.5 h at
15‡C. Subsequently the cellular supernatants were removed by aspira-
tion and the cells were washed with ice-cold PBS prior to lysis with
bu¡er containing 20 mM HEPES, 150 mM NaCl, 10% v/v glycerol,
1% w/v Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, pH 7.5. Bound
counts were determined in a Packard Q-counter after transfer of the
cell lysates to individual tubes. Assays were performed three times,
with each data point being determined in triplicate and Kd and IC50
values þ standard error of the mean are reported. Binding constants
were determined using the Ligand program [31].
3. Results
The e¡ects of replacing residues 260^277 of human insulin
receptor (hIR) with residues 253^266 of hIGF-IR (see Fig. 1)
on proreceptor processing and assembly in 293T cells were
analysed by immunoprecipitation and immunoblotting. Im-
munoprecipitation of wild-type hIR from transfected cell ly-
sates with either Mab 83-14 or Mab 83-7, followed by immu-
noblotting with the L-chain Mab CT-1, showed only
processed L-chain subunits (Fig. 2, lanes 2 and 5), although
proreceptor is discernible upon longer exposure (data not
shown). Similarly, direct blotting of lysates expressing wild-
type receptor with Mab CT-1 indicated e⁄cient proreceptor
processing (Fig. 2, lane7). In contrast, the chimaeric prorecep-
tor (hIR-CLX) is processed ine⁄ciently, as indicated by the
disproportionate amount of proreceptor relative to L-chain
detected by Mab CT-1 in cell lysates of transfected cells
(Fig. 2, lane 8), and following immunoprecipitation with
Mab 83-14 (Fig. 2, lane 3). Mab 83-7 still binds hIR-CLX
but exhibits a reduced a⁄nity for the chimaeric receptor com-
pared to the wild-type receptor, based on immunoprecipita-
tion (Fig. 2, lane 5 vs 6) and fails to immunoprecipitate
the hIR-CLX proreceptor, in contrast to 83-14 (Fig. 2, lane
3 vs 6).
Fig. 1. Mutagenesis of hIR cDNA. Residues 254^284 of the amino acid sequence of hIR are shown, and immediately below is the nucleotide
sequence of hIR cDNA encoding this region; the nucleotide sequence changed in the mutant through site-directed mutagenesis is in bold. The
78 residue oligonucleotide used in mutagenesis and the amino acid sequence of the resulting hIR/IGF-1R chimaera obtained from the construc-
tion are shown below the hIR cDNA sequence. The segment of this mutant oligonucleotide sequence used as a probe, to identify clones that
had incorporated the mutation, is underlined.
Fig. 2. Immunoreactivity of wild-type and chimaeric insulin recep-
tors with Mabs 83-7 and 83-14. 293T ¢broblasts transfected with
plasmid DNA encoding wild-type (hIR), chimaeric (hIR-CLX) re-
ceptors and a negative control vector (L-gal) were lysed and immu-
noprecipitated with monoclonal antibodies (83-14 or 83-7) speci¢c
for the receptor K-subunit. Immunoprecipitated samples (lanes 1^6),
together with aliquots of total cell lysate from receptor-transfected
cells (lanes 7,8), were immunoblotted with the L-chain-speci¢c
monoclonal antibody, CT-1. IgH refers to the IgG heavy chain of
the precipitating Mab.
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Competition binding assays, in which 125I-insulin is dis-
placed by unlabelled insulin, showed that insulin binding by
hIR-CLX and hIR did not di¡er signi¢cantly (Fig. 3A). Anal-
ysis of the binding data produces similar dissociation con-
stants for both receptors (hIR: Kd1 = 2.1 þ 0.9U10310,
Kd2 = 7.2 þ 2.0 1039 and hIR-CLX: Kd1 = 1.1 þ 0.1U10310,
Kd2 = 1.6 þ 0.6 1039). However, competitive binding assays us-
ing 125I-insulin and unlabelled IGF-1 as the competing ligand
show a substantial (10 fold) di¡erence between hIR and hIR-
CLX (Fig. 3B); IGF-1 displacing 125I-insulin bound to hIR-
CLX more easily than 125I-insulin bound to hIR (hIR-CLX,
IC50 = 5.7 þ 2.0U1039 M; hIR, IC50 = 5.7 þ 2.2U1038 M).
Competitive binding studies were also carried out in triplicate
on hIR and hIR_CLX expressed in COS cells. There was no
di¡erence in capacity of insulin to displace 125I-insulin from
either construct (not shown) while the capacity of IGF-1 to
displace 125I-insulin from hIR_CLX was 12 times greater than
its ability to displace radiolabelled ligand from wild-type hIR
(not shown).
4. Discussion
The Cys-rich region of IGF-1R has been shown to be an
important determinant of IGF-1 binding speci¢city. An anal-
ysis of 12 IR/IGF-1R chimaeras showed that the IGF-1 spe-
ci¢city determinants were located between IGF-1R residues
132^315 [17,18]. IR-based chimaeras, containing residues 1^
514, 1^315 or 132^315 from IGF-1R, bound IGF-1 with high
a⁄nity while chimaeras 132^315 from IGF-1R did not [17,18].
The binding speci¢city determinant could be further narrowed
to residues 184^279, based on the binding characteristics of a
series of IR/IGF-1R ectodomain chimaeras: a chimaera con-
taining residues 1^284 from IGF-1R, bound IGF-1 with high
a⁄nity [15], another chimaera containing IGF-1R residues 1^
180 bound neither ligand [16], while a chimaera containing
residues 184^279 of IGF-1R bound both insulin and IGF-1
with high a⁄nity [16]. The di¡erential binding speci¢cities of
IR-based chimaeric whole receptors containing residues 1^217
of IGF-1R (which bound insulin preferentially) and 1^274 of
IGF-1R (which bound IGF-1 preferentially), mapped the lo-
cation of the IGF-1 speci¢city determinants to residues 223^
274 of IGF-1R, since residues 218^222 are conserved between
IGF-1R and IR [14].
In this report we have further narrowed the region control-
ling IGF-1 discrimination to the variable loop (IGF-1R resi-
dues 253^266) in module 6 of the Cys-rich region. The chi-
maeric receptor hIR-CLX was not signi¢cantly di¡erent from
wild-type hIR in terms of insulin binding a⁄nity, but was
more amenable to displacement of 125I-insulin by IGF-1
than was hIR. High-resolution structural information is re-
quired to establish whether this loop makes direct contact
with IGF-1 in the ligand/receptor complex or whether the
poorer binding of IGF-1 by IR is due to steric constraints
imposed by the loop.
Studies on IGF-1 have shown that replacement of the C
region by a four residue glycine linker reduced a⁄nity for
IGF-1R by 40^100 fold [32,33] with a 10 fold reduction [32]
or a small increase [33] in binding to IR. Alanine mutants of
IGF-1 have implicated Arg-21, Arg-36 and Arg-37 in IGF-1R
binding [34]. The region of the receptor responsible for recog-
nising Arg-36 and Arg-37 is the Cys-rich region 217^284 [35]
which has eight acidic residues not found in the corresponding
positions in IR. Six of these line the putative binding pocket,
including the three in the loop region which when exchanged
(hIR-CLX) dramatically a¡ected the displacement of bound
insulin by IGF-1. Thus it seems likely that electrostatic inter-
actions play an important part in IGF-1 binding, with the
positively charged C region having an orientational role in
the binding of IGF-1 to the acidic patch of residues in the
central region of the Cys-rich domain.
The hIR-CLX chimaera provided an opportunity to further
map the residues involved in the epitope for Mab 83-7 [19].
This antibody reduced insulin binding to adipocytes by only
10% and was insulin mimetic, but at 20 times higher molar
ratio than insulin [36]. The epitope of mouse Mab 83-7 resides
between residues 191 and 297 in the Cys-rich region of hIR
[11,20] which has seven residues di¡erent from mouse IR [23],
four of which occur in the exchanged loop. The fact that hIR-
CLX (in which all 14 amino acid residues encompassing the
exchanged loop di¡er from those in the wild-type hIR), can
still be recognised by Mab 83-7, indicates that the module 6
loop of hIR does not contribute substantially to the epitope.
Fig. 3. Competition binding curves for 125I-insulin binding to 293
cells expressing hIR and hIR-CLX. 293T ¢broblasts expressing hIR
or hIR-CLX were incubated with 125I-insulin and varying concentra-
tions of unlabelled insulin or IGF-1. The amount of 125I-insulin
bound, as a percentage of 125I-insulin bound in the absence of unla-
belled hormone, is plotted against the concentration of unlabelled
insulin (A) or IGF-1 (B). The plots shown are from a representative
experiment. Error bars indicate the standard error of the mean.
Curve ¢tting to data was performed using non-linear regression
analysis on GraphPad Prism (GraphPad Software).
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Of the remaining three sequence di¡erences between mouse
and human IR in the region 191^297, residue 218 is adjacent
to an N-linked glycosylation site at 215 and thus likely to be
obscured by oligosaccharide. This leaves residues 210 in the
third Cys-rich module and 236 in the fourth Cys-rich module,
as the major contributors to the epitope on hIR for the mouse
monoclonal antibody 83-7. In the three-dimensional structure
of hIGF-1R, the residues equivalent to 210 and 236 of hIR
are in close proximity at 12 Aî [3], in a location that is con-
sistent with the single molecule images of hIR/83-7 Fab com-
plexes [37]. In addition, the closest residues of the loop are
approximately 40 Aî distant on an opposite face of the mole-
cule to residues 210 and 236, and are unlikely to form part of
the same epitope as residues 210 and 236.
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